The Voucher and the Waiting Room: What Psilocybin FDA Approval Will Actually Mean for Your Practice

A client I've worked with for years, someone with treatment-resistant depression who has been through more medication trials than either of us enjoys counting, brought a screenshot to a recent session. It was a headline about the FDA fast-tracking psilocybin. Their question was entirely practical: should they skip the next medication trial and wait for this instead?

That question deserves a precise answer, and the headlines don't provide one. Psilocybin FDA approval has moved from speculation to a plausible 2027 event. What hasn't moved is everything that determines whether my client, or yours, will ever be able to access it. So here is the precise version: where approval actually stands, what it will and won't create, and what I told my client about waiting.

Compass Pathways announced in February 2026 that both of its Phase 3 trials of COMP360, a synthetic psilocybin formulation for treatment-resistant depression, met their primary endpoints. In COMP006, two 25 mg doses outperformed a 1 mg control by 3.8 points on the MADRS (Montgomery–Åsberg Depression Rating Scale), with improvement appearing the day after administration and holding through week six. The earlier trial, COMP005, showed a 3.6-point separation from placebo.

Read those numbers plainly. A 3.6-to-3.8-point MADRS separation is statistically robust and clinically real for a treatment-resistant population. It is also modest. In the 25 mg arm of COMP006, 39% of participants achieved a clinically meaningful response, which means most didn't. Psilocybin for treatment-resistant depression shows genuine promise; it is not the ending of depression that some coverage suggests. Serious adverse events involving suicidality occurred at rates below 1%, which is low and also not zero, a distinction that matters when you're the one doing the screening.

Two more pieces moved this spring. On April 18, 2026, the White House issued an executive order, Accelerating Medical Treatments for Serious Mental Illness, directing the FDA to grant priority review vouchers to psychedelic drugs holding Breakthrough Therapy designation, and directing the attorney general to complete rescheduling review "as quickly as practicable" for any Schedule I product that completes Phase 3 and earns approval. Six days later, the FDA issued priority vouchers to Compass's COMP360, to the nonprofit Usona Institute's psilocybin program for major depressive disorder, and to Transcend Therapeutics' methylone for PTSD.

The likely sequence: Compass completes its rolling new drug application in late 2026, the FDA reviews on an accelerated clock, and, if approved, the DEA reschedules the approved product. Note the precision there. Rescheduling would apply to COMP360 as an approved drug, not to psilocybin generally. The mushroom remains Schedule I; the pharmaceutical doesn't.

Approval creates a drug. It does not create a treatment system.

The COMP360 protocol involves a monitored session lasting six to eight hours, with trained staff present throughout, plus preparation beforehand and integration afterward. That is not a prescription your client picks up at a pharmacy. It's closer to a day surgery in staffing terms, except that no CPT code exists for it, no insurer has committed to covering it, and no workforce has been trained at scale to deliver it. The executive order, for all its acceleration language, says nothing about reimbursement, clinician training, or delivery infrastructure. It speeds up the part of the pipeline that produces a sellable product and leaves the part that produces actual care exactly where it was.

This isn't an oversight unique to one administration; it's the standard shape of American drug development, which optimizes for approval because approval is where the return on investment lives. The work of making a treatment exist for people (coverage, workforce, settings, equity of access) belongs to nobody in particular, which is how it reliably doesn't get done. Ketamine showed us this film already: an approved medicine, an infrastructure vacuum, and a market that filled the vacuum by cutting the expensive parts. Without deliberate effort, psilocybin's rollout will follow the same script at a higher price point, and the clients who could most use a genuinely new option for treatment-resistant depression (disproportionately poor, rural, publicly insured) will watch it launch in boutique clinics they can't reach.

If you're a licensed clinician without psychedelic specialization, here is my read on what's worth doing in the next year, and what isn't.

Get accurate on the timeline, because your clients are asking. "Approval is plausible in 2027, access will lag well behind it, and treatment-resistant depression is the indication" is an answer you can stand behind. It's also more useful than enthusiasm. As for my client's actual question: waiting for a treatment with no approval date, no price, and no coverage pathway is not a treatment plan, and we proceeded with the next option in front of us.

Don't buy a five-figure certification on spec. No approved treatment exists yet, no payer has defined what credentials it will require, and the training market is already selling readiness for a system that hasn't been designed. Foundational education (pharmacology, screening, contraindications, the evidence base with its limitations) costs very little and won't be wasted regardless of what the FDA decides. The expensive bet can wait until there's something to bet on.

Expect the clients you already have to get there first. Long before an approved product reaches a clinic near you, your clients will encounter psilocybin through Oregon's and Colorado's state programs, through New Mexico's medical program launching in December, or without any program at all. The clinical skills that matter now are the unglamorous ones: screening knowledge, harm reduction conversations, and integration work with clients who arrive having already had the experience.

Watch the access fight, not just the approval. Whether this becomes medicine or a luxury good is being decided now, in rulemaking and reimbursement decisions that get a fraction of the headlines. New Mexico just funded psilocybin treatment for low-income patients by statute, proof that access-by-design is a choice available to us. The approval is coming either way. What we build around it is not yet settled, and clinicians have standing to say so.

Plausibly in 2027, not sooner. Compass Pathways' two Phase 3 trials of COMP360 for treatment-resistant depression met their primary endpoints, and a 2026 executive order with priority review vouchers sped up the FDA clock. Compass expects to complete its rolling application in late 2026, with review and possible rescheduling of the approved product to follow.

Genuinely promising but modest. The Phase 3 trials showed a 3.6-to-3.8-point MADRS separation from control, which is statistically robust and clinically real for this population. But in the 25 mg arm of COMP006, about 39% achieved a clinically meaningful response, meaning most did not. Serious adverse events involving suicidality occurred at rates below 1%.

No. The COMP360 protocol involves a monitored six-to-eight-hour session with trained staff, plus preparation and integration, closer to a day surgery than a pharmacy pickup. No billing code, insurer commitment, or trained workforce exists at scale yet. Approval also reschedules only the approved product, not psilocybin generally; the mushroom stays Schedule I.

Not an expensive one on spec. No approved treatment exists, no payer has defined required credentials, and the training market is selling readiness for a system that isn't designed. Foundational education (pharmacology, screening, contraindications, the evidence and its limits) is cheap and won't be wasted. The five-figure bet can wait until there is something to bet on.

Peter Addy, PhD, LPC, LMHC is a Portland-based licensed therapist and the founder of Psychedelic Affirming Education, an NBCC-approved continuing education provider for licensed mental health professionals and Oregon Psilocybin Services facilitators. His research background includes work at Yale School of Medicine on psychedelic substances.

Stay oriented as this unfolds: Our newsletter tracks the regulatory and research developments that actually affect clinical practice.